Study: Planned budget cuts would hurt drug development badly

Significant reductions in the federal budget could severely impact agencies responsible for scientific funding. A proposed 40% cut to the National Institutes of Health (NIH) has raised alarms among biomedical researchers and the industries that depend on their work. According to a recent study published in Science, researchers have sought to quantify the potential repercussions of these cuts. They analyzed historical data to determine the number of grants that would have been affected by similar budget reductions in the past. Their findings indicate that approximately half of the newly approved drugs in recent years were developed with funding from grants that would be eliminated under the proposed budget. While it remains uncertain whether these cuts will be enacted, Congress is currently considering maintaining funding levels for most scientific agencies. However, the prospect of budget reductions looms large, with fears that they will disproportionately impact the 20 institutes within the NIH as the administration hints at consolidation. To illustrate the potential fallout, researchers made a critical assumption: every NIH institute would experience a uniform 40% budget decrease. They utilized a priority score system, which ranks grant submissions based on their merit, to identify which projects would be cut. By simulating a smaller budget, the study effectively pinpointed grants that would have been funded under the current budget but would be left unfunded following extensive cuts, emphasizing the risks to future drug innovation.